Showing 1 - 8 results of 8 for search 'Howard S. Hochster', query time: 0.04s Refine Results
  1. 1
    Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

    Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis by Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. Hochster

    Published 2023-01-01
    Get full text
    Article
  2. 2
    Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

    Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A ra... by E. Gabriela Chiorean, Vincent Picozzi, Chung‐Pin Li, Marc Peeters, Joan Maurel, Jaswinder Singh, Talia Golan, Jean‐Frédéric Blanc, Sonya C. Chapman, Anwar M. Hussain, Erica L. Johnston, Howard S. Hochster

    Published 2023-10-01
    Get full text
    Article
  3. 3
    Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research

    Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research by Ritesh Kumar, Jongmyung Kim, Matthew P. Deek, Mariam F. Eskander, Prateek Gulhati, Haejin In, Timothy Kennedy, Mihir M. Shah, Miral S. Grandhi, Lyudmyla Berim, Kristen R. Spencer, Russell C. Langan, Howard S. Hochster, Patrick M. Boland, Salma K. Jabbour

    Published 2023-07-01
    Get full text
    Article
  4. 4
    Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

    Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. by Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro

    Published 2013-01-01
    Get full text
    Article
  5. 5
    Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

    Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. by Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro

    Published 2021-01-01
    Get full text
    Article
  6. 6
    Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

    Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. by Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro

    Published 2022-01-01
    Get full text
    Article
  7. 7
    Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

    Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer by Robert H. Shoemaker, Reynold A. Panettieri, Steven K. Libutti, Howard S. Hochster, Norman R. Watts, Paul T. Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M. White, Quentin Lawrence, Jeremy Boone, Jason D. Marshall, Rebecca L. Matthews, Brian D. Cholewa, Jeffrey W. Richig, Ben T. Chen, David L. McCormick, Romana Gugensberger, Sonja Höller, Josef M. Penninger, Gerald Wirnsberger

    Published 2022-01-01
    Get full text
    Article
  8. 8
    Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.

    Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. by Robert H Shoemaker, Reynold A Panettieri, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, Brian D Cholewa, Jeffrey W Richig, Ben T Chen, David L McCormick, Romana Gugensberger, Sonja Höller, Josef M Penninger, Gerald Wirnsberger

    Published 2022-01-01
    Get full text
    Article

Search Tools: